HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Rheumatology5970 papers

Rheumatoid arthritis

Last edited: 4/23/2026

Overview

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by symmetric joint inflammation, leading to pain, swelling, and potential joint destruction. It significantly impacts quality of life and increases cardiovascular risk. 1 3 19

Diagnosis

Clinical Criteria: Morning stiffness, joint swelling, synovitis, and symmetrical joint involvement.

Laboratory Tests: Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), rheumatoid factor (RF), and anti-citrullinated protein antibodies (ACPA).

Imaging: Radiographic evidence of erosions and joint space narrowing; ultrasound and MRI for synovitis assessment. 9 3 19

Management

First-Line Treatments:

- Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate (initial dose typically 7.5-20 mg/week). - Biologics: If inadequate response to DMARDs, consider TNF inhibitors (e.g., adalimumab, infliximab) or other biologics like rituximab or tofacitinib.

Adjunctive Treatments:

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for pain relief. - Glucocorticoids: Short-term use for acute flares. - Physical Therapy: To maintain joint function and mobility. - Cardiovascular Risk Management: Statins recommended for patients with atherosclerotic cardiovascular disease. 1 3 15 20 28

Special Populations

Pregnancy: Use of DMARDs and biologics requires careful consideration; leflunomide is contraindicated; TNF inhibitors and tofacitinib should be discontinued before conception; MTX can be continued under strict monitoring. 11 31

Elderly: Focus on minimizing adverse effects, considering comorbidities; tailored treatment plans with close monitoring. 18

Comorbidities: Increased cardiovascular risk necessitates vigilant management with statins and lifestyle modifications. 19 20 28

Key Recommendations

Early and Aggressive Treatment: Initiate DMARD therapy within 3 months of diagnosis, escalating to biologic agents if necessary. (Evidence: Strong 1)

Risk Stratification: Use EULAR/ACR criteria for risk stratification in patients with arthralgia to identify those at high risk of developing RA. (Evidence: Moderate 3)

Cardiovascular Monitoring: Regularly assess cardiovascular risk factors and consider statin therapy for patients with RA and atherosclerotic cardiovascular disease. (Evidence: Moderate 20)

Patient-Initiated Follow-Up (PIFU): Implement PIFU models to enhance patient autonomy and optimize resource utilization. (Evidence: Expert opinion 7)

Interdisciplinary Care: Utilize interdisciplinary team-based models to improve patient outcomes and satisfaction. (Evidence: Moderate 4)

References

Showing 100 most recent of 3047 indexed papers.

1 Santos Moreno P, García Salinas R, Caballero Uribe CV, Brance ML, Marín Zúcaro NM, Arrieta Vega D et al.. Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis. The Lancet. Rheumatology 2026. link00259-0) 2 Matsui T, Fusama M, Kawahata K, Sakai R, Sugihara T, Tsujimura M et al.. Awareness of social insurance, welfare systems, and home medical care among rheumatologists in Japan: a cross-sectional study. Modern rheumatology 2026. link 3 van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB et al.. EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia. Arthritis & rheumatology (Hoboken, N.J.) 2026. link 4 Sraka G, Ladak Z, Laur C, To D, Oliva L, Barnes C et al.. "It's Like a One-Stop-Shop": A Qualitative Study Exploring Patient Experiences With Interdisciplinary Team-Based Rheumatology Care. The Journal of rheumatology 2026. link 5 Widdifield J, Laur C, Kwok TSH, Oliva L, Appleton CT, Ahluwalia V et al.. Evaluating Implementation Context to Prepare for Scaling Up the Integration of Interdisciplinary Healthcare Providers in Rheumatology Practices: A Rheumatology Workforce Survey. The Journal of rheumatology 2026. link 6 Costello RE, Parker M, Kennedy J, Brophy S, Mehrkar A, Bacon S et al.. Outpatient hospital attendances in people with rheumatoid arthritis during the COVID-19 pandemic and beyond: a cohort study in three nations of the UK. Rheumatology (Oxford, England) 2026. link 7 Jennings AE, Bosworth A, Brooke M, Eddison J, Galloway J, Perry MG et al.. Development of patient-initiated follow-up resources for UK rheumatology departments: a co-design study with patient and clinician collaboration. The Lancet. Rheumatology 2026. link00372-8) 8 Jansen M, Bakker MM, Sepriano AR, Shkedy Z, Landewé RL, Ramiro S et al.. Use of clustering techniques for clinical and epidemiological research: practical tips using an example from rheumatology. Journal of clinical epidemiology 2026. link 9 Terslev L, D'Agostino MA. EULAR-OMERACT consensus-based scoring system for synovitis 10 years later: a validated tool for routine care and clinical trials. RMD open 2026. link 10 Li S, Zhao Q, Cai X, He X, Li S, Chen Z et al.. Rheumatoid arthritis and gout: a rare combination or overlooked coexistence?. Arthritis research & therapy 2026. link 11 Lehoczki A, Ungvari Z, Szappanos Á, Fekete M, Gunkl-Tóth L, Nagy G. Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity. GeroScience 2026. link 12 Noori A, Amini-Bayat Z, Mirdamadi S, Azizmohseni F, Borhani S. A Safer Lytic Alternative: Multi-omics and Immunoinformatics Reveal Reduced Inflammatory Impact of a Chimeric Endolysin Against Antibiotic-induced Immune Dysregulation. Iranian journal of allergy, asthma, and immunology 2026. link 13 Nocenti M, Montastruc F, Degboe Y, Guilleminault L. Asthma Reporting with Anti-TNFα Drugs used in Inflammatory Joint Diseases: A Vigibase® Study with Disproportionality Analysis. Lung 2026. link 14 Zhou J, Cai R, Niu P, Chen T, Guo G, Zeng X et al.. Venous thromboembolism events associated with tofacitinib in rheumatoid arthritis patients: a real-world study from FAERS database. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 15 Cimmino G, Mauro D, Morello M, Titolo G, Iacono D, Forte G et al.. Tofacitinib attenuates IL-6-mediated endothelial tissue factor induction in vitro without affecting platelet aggregation in vivo: mechanistic insights into cardiovascular risk in rheumatoid arthritis. Clinical and experimental rheumatology 2026. link 16 Wu CL, Lu JW, Ho YJ, Lui SW, Hsieh TY, Jheng WL et al.. Deep Immunophenotyping Reveals a Resilient Tph-ABC Axis in Difficult-to-treat Rheumatoid Arthritis: A Case Report of JAK Inhibitor Failure Complicated by Herpes Zoster and Thrombosis. In vivo (Athens, Greece) 2026. link 17 Derksen VFAM, Lindschou J, Winkel P, Delgado GE, de Moel EC, Huizinga TWJ et al.. Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts. Annals of the rheumatic diseases 2026. link 18 Zhang S, Wang H, Jin Z, Cai X. Geriatric nutritional risk index and mortality risk in elderly patients with rheumatoid arthritis: evidence from NHANES (1999-2018). Clinical rheumatology 2026. link 19 Šukara G, Tečer J, Jurin I, Golob M, Barešić M, Mitrović J. Heart Failure in Rheumatoid Arthritis: Epidemiology, Pathogenesis, Diagnosis, Treatment, and Emerging Insights-A Comprehensive Review. Medicina (Kaunas, Lithuania) 2026. link 20 Giles JT, Charles-Schoeman C, Buch MH, Dougados M, Szekanecz Z, Mikuls TR et al.. Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Annals of the rheumatic diseases 2026. link 21 Shin A, Kang S, Jung J, Cho IY, Han K, Kim S et al.. The association between rheumatoid arthritis and stroke risk by serologic status and stroke subtypes. International journal of stroke : official journal of the International Stroke Society 2026. link 22 Su QY, Wang MY, Yang L, Xue CQ, Cheng JW, Liang ZQ et al.. Association of Th17/Treg immune imbalance and cardiovascular complications in RA patients: retrospective cohort study in refractory subgroups. Clinical rheumatology 2026. link 23 Duan H, Jiang C, Zhang B, Meng H, Zhou W, Yan W et al.. Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta-Analysis. Clinical pharmacology and therapeutics 2026. link 24 Karpouzas GA, Cosedis Enevoldsen F, Rezaeian P, Masic D, Budoff MJ, Hauge EM et al.. Pericoronary fat attenuation and its association with atherosclerosis in rheumatoid arthritis compared with controls: a cross-sectional study. RMD open 2026. link 25 David P, Macleod T, Altaie A, Shi Y, Abacar K, Giryes S et al.. Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis. Annals of the rheumatic diseases 2026. link 26 Kang S, Eun Y, Han K, Jung J, Lee S, Cha HS et al.. Increased atrial fibrillation risk in rheumatoid arthritis: Greater in seropositive than seronegative patients. Heart rhythm 2026. link 27 Zheng X, Ke X, Gao J, Luo X, Yang F, Xu Y et al.. Association between sex-hormone binding globulin and cardiovascular events in patients with rheumatoid arthritis. Clinical rheumatology 2026. link 28 Zhuo C, Chen L, Sun X, Chen T, Cai H, Hu X. Association of Disease-Modifying Antirheumatic Drugs (DMARDs) with Cardiovascular Diseases: Evidence from a Drug Target Mendelian Randomization Study. Global heart 2026. link 29 Angeloudi E, Anyfanti P, Gavriilaki E, Pagkopoulou E, Spanou KV, Bekiari E et al.. Asymmetric dimethylarginine and vascular injury in rheumatoid arthritis, from capillaries to large vessels: results from a cross-sectional study. Clinical rheumatology 2026. link 30 Harigai M, Kaneko Y, Tanaka E, Hirata S, Kameda H, Kaneko K et al.. 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication. Modern rheumatology 2025. link 31 Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO et al.. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Annals of the rheumatic diseases 2025. link 32 Sundus H, Khan ZA, Rashid H, Agarwal A, Khan SA. Effect of Different Physiotherapeutic Interventions in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Musculoskeletal care 2025. link 33 Chen S, Wu Y, Huang W, Zhou J, Wei Z, Wu X. Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis. Journal of clinical pharmacology 2025. link 34 Zhou Q, Zhu S, Dai S, Wu Q, Zheng J, Zhu H et al.. Comparison of the efficacy of Janus kinase inhibitors and adalimumab in rheumatoid arthritis: a meta-analysis. Clinical and experimental rheumatology 2025. link 35 Zuckerman BP, Gibson M, Roy R, Hughes M, Mehta D, Yang Z et al.. Abatacept and the risk of malignancy: a meta-analysis across disease indications. Rheumatology (Oxford, England) 2025. link 36 Shao Z, Xia D, Zhou L, Xu Z, Wang J. Immunoinflammatory evidence of rheumatoid arthritis caused by COVID-19. Biological research 2025. link 37 El Binoune I, Bahiri R, El Maghraoui A, Haddouch A, Bencharif I, Slimani S et al.. CEMIR Consensus guidelines among North Africa Rheumatologists for the use of Ultrasound in Rheumatoid Arthritis. La Tunisie medicale 2025. link 38 Lautenschlager C, Stropes A, Smith A, Knell ME, Sperry M. Systematic review and meta-analysis of analgesic treatment options in patients with rheumatoid arthritis related pain. Advances in rheumatology (London, England) 2025. link 39 Nazir MM, Farzeen I, Fasial S, Ashraf A. Berberine in rheumatoid arthritis: a comprehensive review and meta-analysis of its anti-inflammatory and immunomodulatory mechanisms in animal models. Inflammopharmacology 2025. link 40 Qooja S, Roberts MJ, Fakher N, Demashkieh M, Moorthy A, Bishop NC. Is T-cell senescence associated with inflammatory arthritis and disease burden? A systematic review. Seminars in arthritis and rheumatism 2025. link 41 . Special Issue: ACR Convergence 2025 October 24-29, 2025 Chicago, IL. Arthritis & rheumatology (Hoboken, N.J.) 2025. link 42 Holers VM. Rheumatoid arthritis prevention: We need to identify new targets for "NextGen" therapeutic trials. Seminars in arthritis and rheumatism 2025. link 43 Cubberley C, Maharaj A. Global RA treatment recommendations: An update from the various international societies. Best practice & research. Clinical rheumatology 2025. link 44 Nagy G, Buch MH. Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis. RMD open 2025. link 45 Blau BJ, Mandl LA. Rheumatology: What You May Have Missed in 2024. Annals of internal medicine 2025. link 46 Clowse MEB, Federspiel JJ, Wheeler S, Sims CA, Swezey T, Corneli A et al.. Moving the ACR's Reproductive Health Guidelines Into Practice: A Quantitative and Qualitative Assessment of a Novel Reproductive Rheumatology ECHO. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2025. link 47 Bilgin E, Venerito V, Bogdanos DP. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. Autoimmunity reviews 2025. link 48 Kaplan H, Cengiz G, Kara H, Cüce İ, Kirnap M, Çaliş M. Analysis of data on biosimilar prescription rates in rheumatology practice from a reference center in Turkey. Scientific reports 2025. link 49 Lyon A, Lester S, Stanhope J, Lynch T, Black R, Barrett C et al.. Dual-energy X-ray absorptiometry and anti-osteoporotic medication use in Australian patients with early rheumatoid arthritis using data from the Australian Rheumatology Association Database. Internal medicine journal 2025. link 50 Grainger R, Milne V, Dalbeth N. Rheumatology services in Aotearoa New Zealand-do they meet Arthritis New Zealand/New Zealand Rheumatology Association-endorsed service standards?. The New Zealand medical journal 2025. link 51 Wheeler AM, Riley TR, Merriman TR. Genetic Risk Scores for the Clinical Rheumatologist. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2025. link 52 D'Ignazio E, Corradini D, Cazenave T, Bixio R, Baldi C, Ubhi HK et al.. Ultrasound Beyond Joints: A Review of Extra-Articular Applications in Rheumatology. Current rheumatology reports 2025. link 53 Fusama M, Nakahara H, Kaneko Y, Bennett SE, Ndosi M, Takeuchi T. Acceptability and Barriers to Implementation of the EULAR Recommendations for the Role of the Nurse in the Management of Chronic Inflammatory Arthritis: A Mixed-Methods Study With Nurses and Rheumatologists in Japan. International journal of rheumatic diseases 2025. link 54 Çelik NÇ, Kılınç EA. Assessment of ChatGPT's adherence to EULAR diagnostic criteria and therapeutic protocols for rheumatoid arthritis at two distinct time points, 14 days apart, utilizing binary and multiple-choice inquiries. Clinical rheumatology 2025. link 55 Labinsky H, Klemm P, Graalmann L, Thiele T, Hornig J, Fink D et al.. Patient experiences, attitudes, and profiles regarding artificial intelligence in rheumatology: a German national cross-sectional survey study. Rheumatology international 2025. link 56 Roberts ET, Bansback N, Tseng CW, Shiboski S, Li J, Schmajuk G et al.. Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry. Health services research 2025. link 57 Liu X, Patel AB, Seidel JE, Mosher DP, Hagens J, Marshall DA. Informing equitable access to care: a cross-sectional study of travel burden to primary and rheumatology care for people with rheumatoid arthritis. International journal for equity in health 2025. link 58 Winthrop KL, Bathon J, Kerschbaumer A, Isaacs JD, Mease P, Gottenberg JE et al.. Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. Annals of the rheumatic diseases 2025. link 59 Guillén-Astete CA, Blanco Cáceres B, Arroyo Palomo J, Palomeque Vargas AM, Serrano Warleta M, Ruiz Bejerano AM et al.. Experience after implementation of ultrasound-guided synovial biopsy in a Rheumatology Department. Reumatologia clinica 2025. link 60 Gilvaz VJ, Sudheer A, Reginato AM. Emerging Artificial Intelligence Innovations in Rheumatoid Arthritis and Challenges to Clinical Adoption. Current rheumatology reports 2025. link 61 Tian Y, Jin M, Li H, Li D, Pei Y. Advancements in rheumatoid arthritis immunotherapy: a comprehensive bibliometric analysis of research trends and hotspots (2003-2023). Clinical and experimental rheumatology 2025. link 62 Seoane-Mato D, Sánchez-Alonso F, Guerra-Rodríguez M, González-Dávila E, Díaz-González F. Bibliometric analysis of the scientific production of rheumatology departments in Spain during the 2013-2022 period. Reumatologia clinica 2025. link 63 Cavalcanti BH, Cavalcanti RR, de Souza MC, Pontes-Silva A. Are rheumatology field professionals scientifically prepared to rehabilitate using exercise? A cross-sectional survey. Journal of bodywork and movement therapies 2025. link 64 Başer Taşkın B, Doğru Kılınç A, Karadoğan MT, Çakmak F, Demirkan FG, Aktay Ayaz N. Biologic therapy through caregivers' eyes: insights from a multicenter pediatric rheumatology survey. Expert opinion on biological therapy 2025. link 65 Kremer P, Fink D, Morf H, Labinsky H, Gente K, Aries P et al.. Digital empowerment on hold: DiGA adoption gaps-a German national cross-sectional patient survey study. Rheumatology international 2025. link 66 Russell O, Lester S, Black RJ, Lassere M, Barrett C, March L et al.. Area-Level Socioeconomic Status Impacts Health Care Visit Frequency by Australian Patients With Inflammatory Arthritis: Results From the Australian Rheumatology Association Database. Arthritis care & research 2025. link 67 Lumma F, Knitza J, Mühlensiepen F. Potentials and barriers of digital patient education in rheumatic disease management: an exploratory qualitative interview study. Rheumatology international 2025. link 68 Bryant MJ, Lester S, Russell O, Whittle S, Limaye V, Proudman S et al.. Implementation of a novel patient reported experience measure (PREM) in rheumatology: a cross-sectional online survey of Australian rheumatology outpatients. Rheumatology international 2025. link 69 May S, Darkow R, Knitza J, Boy K, Klemm P, Heinze M et al.. Digital Transformation of Rheumatology Care in Germany: Cross-Sectional National Survey. Journal of medical Internet research 2025. link 70 Sukkar MB, Ainley R, Barrett C, Bond S, Bradbury LA, Briggs AM et al.. Development of the Australian Rheumatology Association Clinical Care Standard for the Diagnosis and Management of Rheumatoid Arthritis in Adults. The Journal of rheumatology 2025. link 71 Kang S, Eun Y, Han K, Jung J, Kim H, Lee S et al.. Risk of incident gout in rheumatoid arthritis from a nationwide cohort study in South Korea. Scientific reports 2025. link 72 Konal O, Bölen F, Güvenç TS, Pehlivan Ö, Batıbay S, Özcan FB et al.. Gout and rheumatoid arthritis are associated with subclinical vascular damage, reduced brachial vasoreactivity and coronary microvascular dysfunction: a case-control study. Rheumatology international 2025. link 73 Yang M, Xie J, Su Y, Xu K, Wen P, Wan X et al.. Genetic causality between insomnia and specific orthopedic conditions: Insights from a two-sample Mendelian randomization study. Experimental gerontology 2025. link 74 Yielder R, Gasteiger C, Pennebaker JW, Douglas M, Dalbeth N, Petrie KJ. Using word clouds to reveal patients' perceptions about their arthritis. Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2025. link 75 Boeing LB, Fogaça NS, Kahlow BS, Skare T, Nisihara R. Polypharmacy and drug interactions in the management of rheumatoid arthritis. Revista da Associacao Medica Brasileira (1992) 2025. link 76 Berthelot W, Sirois C, Julien AS, Amiable N, Bessette L, Desaulniers P et al.. The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study. Rheumatology international 2025. link 77 Feyo VB, Provinciali LS, Rodrigues LSS, Pereira JJ, Gerheim PSAS, de Souza VA et al.. The Silent Gap: An Exploratory Analysis of Severe Periodontal Breakdown in Rheumatoid Arthritis Despite Stable Gingival Crevicular Fluid Levels. International journal of rheumatic diseases 2025. link 78 Rodrigues LSS, Feyo VB, Provinciali LS, Pereira JJ, da Silva CAL, de Souza VA et al.. Association between tooth loss and clinical complications in rheumatoid arthritis: a pilot study. Clinical rheumatology 2025. link 79 Hijjawi N, Tout FS, Azaizeh B, Aljaafreh B. The role of vitamins D, B12, C, and K in modulating inflammation and disease management in rheumatoid arthritis: a comprehensive review. Clinical rheumatology 2025. link 80 Khoroshun K, Bantel C, Hoffmann F, Jobski K. Methotrexate-related drug reactions on kidneys and liver in rheumatoid arthritis: an analysis of spontaneous reports in EudraVigilance. Arthritis research & therapy 2025. link 81 Liu S, Yuan Z, Rao S, Li W, Wu T, Deng S et al.. Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024. Frontiers in immunology 2025. link 82 Mikaeili B, Alqahtani ZA, Hincapie AL, Guo JJ. Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022. Clinical rheumatology 2025. link 83 Goldman A, Raschi E, Druyan A, Sharif K, Lahat A, Ben-Zvi I et al.. Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. United European gastroenterology journal 2025. link 84 Li J, Han ZW, Gao SS, Guo Q, Cang HQ. Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis. Frontiers in immunology 2025. link 85 Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A et al.. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. Drug safety 2025. link 86 Jia G, Guo T, Liu L, He C. Rheumatoid Arthritis, Circulating Inflammatory Proteins, and Hypertension: A Mendelian Randomization Study. Journal of clinical hypertension (Greenwich, Conn.) 2025. link 87 Guajardo-Jauregui N, Cardenas-de la Garza JA, Galarza-Delgado DA, Azpiri-Lopez JR, Arvizu-Rivera RI, Polina-Lugo RL et al.. Inadequate identification of high cardiovascular risk and carotid plaques in rheumatoid arthritis patients by the 2024 Predicting Risk of Cardiovascular EVENTs and the 2013 Atherosclerotic Cardiovascular Disease algorithms: findings from a Mexican cohort. Clinical rheumatology 2025. link 88 Alexandre A, Sá-Couto D, Brandão M, Cabral S, Fonseca T, Costa RQ et al.. Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort. Clinical research in cardiology : official journal of the German Cardiac Society 2025. link 89 Ausserwinkler M, Gensluckner S, Voelkerer A, Thiel J, Neumann HJ, Flamm M et al.. Genetic relationship between rheumatoid arthritis and cardiovascular diseases : A systematic review of Mendelian randomization studies. Wiener klinische Wochenschrift 2025. link 90 Kitai J, Sada RM, Yamaguchi S, Shinde A, Maruyama W. Cognitive Dysfunction as an Initial Manifestation of Rheumatoid Arthritis-associated Intravascular Large B-cell Lymphoma. Internal medicine (Tokyo, Japan) 2025. link 91 Nettleton E, Carlson K, Putman M. The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumatica. The Lancet. Rheumatology 2025. link00227-3) 92 Feng M, Meng F, Jia Y, Wang Y, Ji G, Gao C et al.. Exploration of Risk Factors for Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Retrospective Study. Inflammation 2025. link 93 Cacciapaglia F, Spinelli FR, Erre GL, Piga M, Sakellariou G, Manfredi A et al.. Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology. European journal of internal medicine 2025. link 94 Spandorfer R, Kane K, Pappas DA, Kremer J, Reed G, Curtis JR et al.. New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registry. Seminars in arthritis and rheumatism 2025. link 95 Manilall A, Mokotedi L, Gunter S, Roux RL, Fourie S, Millen AM. Tocilizumab does not ameliorate inflammation-induced left ventricular dysfunction in a collagen-induced arthritis rat model. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2025. link 96 Dutt S, Roul P, Yang Y, Johnson TM, Michaud K, Sauer B et al.. Multimorbidity Patterns and Rheumatoid Arthritis Disease Outcomes: Findings From a Multicenter, Prospective Cohort. Arthritis care & research 2025. link 97 Mastrangelo G, Di Sebastiano P, Palazzo V. Endovascular solutions for symptomatic free-floating thrombus in thoracic aorta in rheumatoid arthritis patients: Two clinical cases. Vascular 2025. link 98 Vera E, Vallvé JC, Linares V, Paredes S, Ibarretxe D, Bellés M. Serum Levels of Trace Elements (Magnesium, Iron, Zinc, Selenium, and Strontium) are Differentially Associated with Surrogate Markers of Cardiovascular Disease Risk in Patients with Rheumatoid Arthritis. Biological trace element research 2025. link 99 Yang L, Wang X, Gu B, Su D. Identifying the genetic association between rheumatoid arthritis and the risk of pulmonary arterial hypertension. Clinical rheumatology 2025. link 100 Govindasamy N, Barman M, Salleh N, Giribabu N, Shahzad H. Effects of 17β estradiol on blood pressure elevation in ovariectomized rats with collagen-induced arthritis via modulation of oxidative stress, inflammation, fibrosis, and apoptosis in the aorta involving TLR4/NOX4/NF-kβ and TGFβ1/fibronectin/α-SMA pathways. Naunyn-Schmiedeberg's archives of pharmacology 2025. link

Original source

[1]
Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis. — Santos Moreno P, García Salinas R, Caballero Uribe CV, Brance ML, Marín Zúcaro NM, Arrieta Vega D et al. The Lancet. Rheumatology (2026)
[2]
Awareness of social insurance, welfare systems, and home medical care among rheumatologists in Japan: a cross-sectional study. — Matsui T, Fusama M, Kawahata K, Sakai R, Sugihara T, Tsujimura M et al. Modern rheumatology (2026)
[3]
EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia. — van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB et al. Arthritis & rheumatology (Hoboken, N.J.) (2026)
[4]
"It's Like a One-Stop-Shop": A Qualitative Study Exploring Patient Experiences With Interdisciplinary Team-Based Rheumatology Care. — Sraka G, Ladak Z, Laur C, To D, Oliva L, Barnes C et al. The Journal of rheumatology (2026)
[5]
Evaluating Implementation Context to Prepare for Scaling Up the Integration of Interdisciplinary Healthcare Providers in Rheumatology Practices: A Rheumatology Workforce Survey. — Widdifield J, Laur C, Kwok TSH, Oliva L, Appleton CT, Ahluwalia V et al. The Journal of rheumatology (2026)
[6]
Outpatient hospital attendances in people with rheumatoid arthritis during the COVID-19 pandemic and beyond: a cohort study in three nations of the UK. — Costello RE, Parker M, Kennedy J, Brophy S, Mehrkar A, Bacon S et al. Rheumatology (Oxford, England) (2026)
[7]
Development of patient-initiated follow-up resources for UK rheumatology departments: a co-design study with patient and clinician collaboration. — Jennings AE, Bosworth A, Brooke M, Eddison J, Galloway J, Perry MG et al. The Lancet. Rheumatology (2026)
[8]
Use of clustering techniques for clinical and epidemiological research: practical tips using an example from rheumatology. — Jansen M, Bakker MM, Sepriano AR, Shkedy Z, Landewé RL, Ramiro S et al. Journal of clinical epidemiology (2026)
[9]
EULAR-OMERACT consensus-based scoring system for synovitis 10 years later: a validated tool for routine care and clinical trials. — Terslev L, D'Agostino MA RMD open (2026)
[10]
Rheumatoid arthritis and gout: a rare combination or overlooked coexistence? — Li S, Zhao Q, Cai X, He X, Li S, Chen Z et al. Arthritis research & therapy (2026)
[11]
Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity. — Lehoczki A, Ungvari Z, Szappanos Á, Fekete M, Gunkl-Tóth L, Nagy G GeroScience (2026)
[12]
A Safer Lytic Alternative: Multi-omics and Immunoinformatics Reveal Reduced Inflammatory Impact of a Chimeric Endolysin Against Antibiotic-induced Immune Dysregulation. — Noori A, Amini-Bayat Z, Mirdamadi S, Azizmohseni F, Borhani S Iranian journal of allergy, asthma, and immunology (2026)
[13]
Asthma Reporting with Anti-TNFα Drugs used in Inflammatory Joint Diseases: A Vigibase® Study with Disproportionality Analysis. — Nocenti M, Montastruc F, Degboe Y, Guilleminault L Lung (2026)
[14]
Venous thromboembolism events associated with tofacitinib in rheumatoid arthritis patients: a real-world study from FAERS database. — Zhou J, Cai R, Niu P, Chen T, Guo G, Zeng X et al. Naunyn-Schmiedeberg's archives of pharmacology (2026)
[15]
Tofacitinib attenuates IL-6-mediated endothelial tissue factor induction in vitro without affecting platelet aggregation in vivo: mechanistic insights into cardiovascular risk in rheumatoid arthritis. — Cimmino G, Mauro D, Morello M, Titolo G, Iacono D, Forte G et al. Clinical and experimental rheumatology (2026)
[16]
Deep Immunophenotyping Reveals a Resilient Tph-ABC Axis in Difficult-to-treat Rheumatoid Arthritis: A Case Report of JAK Inhibitor Failure Complicated by Herpes Zoster and Thrombosis. — Wu CL, Lu JW, Ho YJ, Lui SW, Hsieh TY, Jheng WL et al. In vivo (Athens, Greece) (2026)
[17]
Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts. — Derksen VFAM, Lindschou J, Winkel P, Delgado GE, de Moel EC, Huizinga TWJ et al. Annals of the rheumatic diseases (2026)
[18]
Geriatric nutritional risk index and mortality risk in elderly patients with rheumatoid arthritis: evidence from NHANES (1999-2018). — Zhang S, Wang H, Jin Z, Cai X Clinical rheumatology (2026)
[19]
Heart Failure in Rheumatoid Arthritis: Epidemiology, Pathogenesis, Diagnosis, Treatment, and Emerging Insights-A Comprehensive Review. — Šukara G, Tečer J, Jurin I, Golob M, Barešić M, Mitrović J Medicina (Kaunas, Lithuania) (2026)
[20]
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. — Giles JT, Charles-Schoeman C, Buch MH, Dougados M, Szekanecz Z, Mikuls TR et al. Annals of the rheumatic diseases (2026)
[21]
The association between rheumatoid arthritis and stroke risk by serologic status and stroke subtypes. — Shin A, Kang S, Jung J, Cho IY, Han K, Kim S et al. International journal of stroke : official journal of the International Stroke Society (2026)
[22]
Association of Th17/Treg immune imbalance and cardiovascular complications in RA patients: retrospective cohort study in refractory subgroups. — Su QY, Wang MY, Yang L, Xue CQ, Cheng JW, Liang ZQ et al. Clinical rheumatology (2026)
[23]
Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta-Analysis. — Duan H, Jiang C, Zhang B, Meng H, Zhou W, Yan W et al. Clinical pharmacology and therapeutics (2026)
[24]
Pericoronary fat attenuation and its association with atherosclerosis in rheumatoid arthritis compared with controls: a cross-sectional study. — Karpouzas GA, Cosedis Enevoldsen F, Rezaeian P, Masic D, Budoff MJ, Hauge EM et al. RMD open (2026)
[25]
Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis. — David P, Macleod T, Altaie A, Shi Y, Abacar K, Giryes S et al. Annals of the rheumatic diseases (2026)
[26]
Increased atrial fibrillation risk in rheumatoid arthritis: Greater in seropositive than seronegative patients. — Kang S, Eun Y, Han K, Jung J, Lee S, Cha HS et al. Heart rhythm (2026)
[27]
Association between sex-hormone binding globulin and cardiovascular events in patients with rheumatoid arthritis. — Zheng X, Ke X, Gao J, Luo X, Yang F, Xu Y et al. Clinical rheumatology (2026)
[28]
Association of Disease-Modifying Antirheumatic Drugs (DMARDs) with Cardiovascular Diseases: Evidence from a Drug Target Mendelian Randomization Study. — Zhuo C, Chen L, Sun X, Chen T, Cai H, Hu X Global heart (2026)
[29]
Asymmetric dimethylarginine and vascular injury in rheumatoid arthritis, from capillaries to large vessels: results from a cross-sectional study. — Angeloudi E, Anyfanti P, Gavriilaki E, Pagkopoulou E, Spanou KV, Bekiari E et al. Clinical rheumatology (2026)
[30]
2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication. — Harigai M, Kaneko Y, Tanaka E, Hirata S, Kameda H, Kaneko K et al. Modern rheumatology (2025)
[31]
EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. — Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO et al. Annals of the rheumatic diseases (2025)
[32]
Effect of Different Physiotherapeutic Interventions in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. — Sundus H, Khan ZA, Rashid H, Agarwal A, Khan SA Musculoskeletal care (2025)
[33]
Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis. — Chen S, Wu Y, Huang W, Zhou J, Wei Z, Wu X Journal of clinical pharmacology (2025)
[34]
Comparison of the efficacy of Janus kinase inhibitors and adalimumab in rheumatoid arthritis: a meta-analysis. — Zhou Q, Zhu S, Dai S, Wu Q, Zheng J, Zhu H et al. Clinical and experimental rheumatology (2025)
[35]
Abatacept and the risk of malignancy: a meta-analysis across disease indications. — Zuckerman BP, Gibson M, Roy R, Hughes M, Mehta D, Yang Z et al. Rheumatology (Oxford, England) (2025)
[36]
Immunoinflammatory evidence of rheumatoid arthritis caused by COVID-19. — Shao Z, Xia D, Zhou L, Xu Z, Wang J Biological research (2025)
[37]
CEMIR Consensus guidelines among North Africa Rheumatologists for the use of Ultrasound in Rheumatoid Arthritis. — El Binoune I, Bahiri R, El Maghraoui A, Haddouch A, Bencharif I, Slimani S et al. La Tunisie medicale (2025)
[38]
Systematic review and meta-analysis of analgesic treatment options in patients with rheumatoid arthritis related pain. — Lautenschlager C, Stropes A, Smith A, Knell ME, Sperry M Advances in rheumatology (London, England) (2025)
[39]
Berberine in rheumatoid arthritis: a comprehensive review and meta-analysis of its anti-inflammatory and immunomodulatory mechanisms in animal models. — Nazir MM, Farzeen I, Fasial S, Ashraf A Inflammopharmacology (2025)
[40]
Is T-cell senescence associated with inflammatory arthritis and disease burden? A systematic review. — Qooja S, Roberts MJ, Fakher N, Demashkieh M, Moorthy A, Bishop NC Seminars in arthritis and rheumatism (2025)
[41]
Special Issue: ACR Convergence 2025 October 24-29, 2025 Chicago, IL. Arthritis & rheumatology (Hoboken, N.J.) (2025)
[42]
Rheumatoid arthritis prevention: We need to identify new targets for "NextGen" therapeutic trials. — Holers VM Seminars in arthritis and rheumatism (2025)
[43]
Global RA treatment recommendations: An update from the various international societies. — Cubberley C, Maharaj A Best practice & research. Clinical rheumatology (2025)
[44]
Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis. — Nagy G, Buch MH RMD open (2025)
[45]
Rheumatology: What You May Have Missed in 2024. — Blau BJ, Mandl LA Annals of internal medicine (2025)
[46]
Moving the ACR's Reproductive Health Guidelines Into Practice: A Quantitative and Qualitative Assessment of a Novel Reproductive Rheumatology ECHO. — Clowse MEB, Federspiel JJ, Wheeler S, Sims CA, Swezey T, Corneli A et al. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2025)
[47]
Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. — Bilgin E, Venerito V, Bogdanos DP Autoimmunity reviews (2025)
[48]
Analysis of data on biosimilar prescription rates in rheumatology practice from a reference center in Turkey. — Kaplan H, Cengiz G, Kara H, Cüce İ, Kirnap M, Çaliş M Scientific reports (2025)
[49]
Dual-energy X-ray absorptiometry and anti-osteoporotic medication use in Australian patients with early rheumatoid arthritis using data from the Australian Rheumatology Association Database. — Lyon A, Lester S, Stanhope J, Lynch T, Black R, Barrett C et al. Internal medicine journal (2025)
[50]
Rheumatology services in Aotearoa New Zealand-do they meet Arthritis New Zealand/New Zealand Rheumatology Association-endorsed service standards? — Grainger R, Milne V, Dalbeth N The New Zealand medical journal (2025)
[51]
Genetic Risk Scores for the Clinical Rheumatologist. — Wheeler AM, Riley TR, Merriman TR Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2025)
[52]
Ultrasound Beyond Joints: A Review of Extra-Articular Applications in Rheumatology. — D'Ignazio E, Corradini D, Cazenave T, Bixio R, Baldi C, Ubhi HK et al. Current rheumatology reports (2025)
[53]
Acceptability and Barriers to Implementation of the EULAR Recommendations for the Role of the Nurse in the Management of Chronic Inflammatory Arthritis: A Mixed-Methods Study With Nurses and Rheumatologists in Japan. — Fusama M, Nakahara H, Kaneko Y, Bennett SE, Ndosi M, Takeuchi T International journal of rheumatic diseases (2025)
[54]
Assessment of ChatGPT's adherence to EULAR diagnostic criteria and therapeutic protocols for rheumatoid arthritis at two distinct time points, 14 days apart, utilizing binary and multiple-choice inquiries. — Çelik NÇ, Kılınç EA Clinical rheumatology (2025)
[55]
Patient experiences, attitudes, and profiles regarding artificial intelligence in rheumatology: a German national cross-sectional survey study. — Labinsky H, Klemm P, Graalmann L, Thiele T, Hornig J, Fink D et al. Rheumatology international (2025)
[56]
Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry. — Roberts ET, Bansback N, Tseng CW, Shiboski S, Li J, Schmajuk G et al. Health services research (2025)
[57]
Informing equitable access to care: a cross-sectional study of travel burden to primary and rheumatology care for people with rheumatoid arthritis. — Liu X, Patel AB, Seidel JE, Mosher DP, Hagens J, Marshall DA International journal for equity in health (2025)
[58]
Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. — Winthrop KL, Bathon J, Kerschbaumer A, Isaacs JD, Mease P, Gottenberg JE et al. Annals of the rheumatic diseases (2025)
[59]
Experience after implementation of ultrasound-guided synovial biopsy in a Rheumatology Department. — Guillén-Astete CA, Blanco Cáceres B, Arroyo Palomo J, Palomeque Vargas AM, Serrano Warleta M, Ruiz Bejerano AM et al. Reumatologia clinica (2025)
[60]
Emerging Artificial Intelligence Innovations in Rheumatoid Arthritis and Challenges to Clinical Adoption. — Gilvaz VJ, Sudheer A, Reginato AM Current rheumatology reports (2025)
[61]
Advancements in rheumatoid arthritis immunotherapy: a comprehensive bibliometric analysis of research trends and hotspots (2003-2023). — Tian Y, Jin M, Li H, Li D, Pei Y Clinical and experimental rheumatology (2025)
[62]
Bibliometric analysis of the scientific production of rheumatology departments in Spain during the 2013-2022 period. — Seoane-Mato D, Sánchez-Alonso F, Guerra-Rodríguez M, González-Dávila E, Díaz-González F Reumatologia clinica (2025)
[63]
Are rheumatology field professionals scientifically prepared to rehabilitate using exercise? A cross-sectional survey. — Cavalcanti BH, Cavalcanti RR, de Souza MC, Pontes-Silva A Journal of bodywork and movement therapies (2025)
[64]
Biologic therapy through caregivers' eyes: insights from a multicenter pediatric rheumatology survey. — Başer Taşkın B, Doğru Kılınç A, Karadoğan MT, Çakmak F, Demirkan FG, Aktay Ayaz N Expert opinion on biological therapy (2025)
[65]
Digital empowerment on hold: DiGA adoption gaps-a German national cross-sectional patient survey study. — Kremer P, Fink D, Morf H, Labinsky H, Gente K, Aries P et al. Rheumatology international (2025)
[66]
Area-Level Socioeconomic Status Impacts Health Care Visit Frequency by Australian Patients With Inflammatory Arthritis: Results From the Australian Rheumatology Association Database. — Russell O, Lester S, Black RJ, Lassere M, Barrett C, March L et al. Arthritis care & research (2025)
[67]
Potentials and barriers of digital patient education in rheumatic disease management: an exploratory qualitative interview study. — Lumma F, Knitza J, Mühlensiepen F Rheumatology international (2025)
[68]
Implementation of a novel patient reported experience measure (PREM) in rheumatology: a cross-sectional online survey of Australian rheumatology outpatients. — Bryant MJ, Lester S, Russell O, Whittle S, Limaye V, Proudman S et al. Rheumatology international (2025)
[69]
Digital Transformation of Rheumatology Care in Germany: Cross-Sectional National Survey. — May S, Darkow R, Knitza J, Boy K, Klemm P, Heinze M et al. Journal of medical Internet research (2025)
[70]
Development of the Australian Rheumatology Association Clinical Care Standard for the Diagnosis and Management of Rheumatoid Arthritis in Adults. — Sukkar MB, Ainley R, Barrett C, Bond S, Bradbury LA, Briggs AM et al. The Journal of rheumatology (2025)
[71]
Risk of incident gout in rheumatoid arthritis from a nationwide cohort study in South Korea. — Kang S, Eun Y, Han K, Jung J, Kim H, Lee S et al. Scientific reports (2025)
[72]
Gout and rheumatoid arthritis are associated with subclinical vascular damage, reduced brachial vasoreactivity and coronary microvascular dysfunction: a case-control study. — Konal O, Bölen F, Güvenç TS, Pehlivan Ö, Batıbay S, Özcan FB et al. Rheumatology international (2025)
[73]
Genetic causality between insomnia and specific orthopedic conditions: Insights from a two-sample Mendelian randomization study. — Yang M, Xie J, Su Y, Xu K, Wen P, Wan X et al. Experimental gerontology (2025)
[74]
Using word clouds to reveal patients' perceptions about their arthritis. — Yielder R, Gasteiger C, Pennebaker JW, Douglas M, Dalbeth N, Petrie KJ Health psychology : official journal of the Division of Health Psychology, American Psychological Association (2025)
[75]
Polypharmacy and drug interactions in the management of rheumatoid arthritis. — Boeing LB, Fogaça NS, Kahlow BS, Skare T, Nisihara R Revista da Associacao Medica Brasileira (1992) (2025)
[76]
The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study. — Berthelot W, Sirois C, Julien AS, Amiable N, Bessette L, Desaulniers P et al. Rheumatology international (2025)
[77]
The Silent Gap: An Exploratory Analysis of Severe Periodontal Breakdown in Rheumatoid Arthritis Despite Stable Gingival Crevicular Fluid Levels. — Feyo VB, Provinciali LS, Rodrigues LSS, Pereira JJ, Gerheim PSAS, de Souza VA et al. International journal of rheumatic diseases (2025)
[78]
Association between tooth loss and clinical complications in rheumatoid arthritis: a pilot study. — Rodrigues LSS, Feyo VB, Provinciali LS, Pereira JJ, da Silva CAL, de Souza VA et al. Clinical rheumatology (2025)
[79]
The role of vitamins D, B12, C, and K in modulating inflammation and disease management in rheumatoid arthritis: a comprehensive review. — Hijjawi N, Tout FS, Azaizeh B, Aljaafreh B Clinical rheumatology (2025)
[80]
Methotrexate-related drug reactions on kidneys and liver in rheumatoid arthritis: an analysis of spontaneous reports in EudraVigilance. — Khoroshun K, Bantel C, Hoffmann F, Jobski K Arthritis research & therapy (2025)
[81]
Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024. — Liu S, Yuan Z, Rao S, Li W, Wu T, Deng S et al. Frontiers in immunology (2025)
[82]
Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022. — Mikaeili B, Alqahtani ZA, Hincapie AL, Guo JJ Clinical rheumatology (2025)
[83]
Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. — Goldman A, Raschi E, Druyan A, Sharif K, Lahat A, Ben-Zvi I et al. United European gastroenterology journal (2025)
[84]
Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis. — Li J, Han ZW, Gao SS, Guo Q, Cang HQ Frontiers in immunology (2025)
[85]
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. — Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A et al. Drug safety (2025)
[86]
Rheumatoid Arthritis, Circulating Inflammatory Proteins, and Hypertension: A Mendelian Randomization Study. — Jia G, Guo T, Liu L, He C Journal of clinical hypertension (Greenwich, Conn.) (2025)
[87]
Inadequate identification of high cardiovascular risk and carotid plaques in rheumatoid arthritis patients by the 2024 Predicting Risk of Cardiovascular EVENTs and the 2013 Atherosclerotic Cardiovascular Disease algorithms: findings from a Mexican cohort. — Guajardo-Jauregui N, Cardenas-de la Garza JA, Galarza-Delgado DA, Azpiri-Lopez JR, Arvizu-Rivera RI, Polina-Lugo RL et al. Clinical rheumatology (2025)
[88]
Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort. — Alexandre A, Sá-Couto D, Brandão M, Cabral S, Fonseca T, Costa RQ et al. Clinical research in cardiology : official journal of the German Cardiac Society (2025)
[89]
Genetic relationship between rheumatoid arthritis and cardiovascular diseases : A systematic review of Mendelian randomization studies. — Ausserwinkler M, Gensluckner S, Voelkerer A, Thiel J, Neumann HJ, Flamm M et al. Wiener klinische Wochenschrift (2025)
[90]
Cognitive Dysfunction as an Initial Manifestation of Rheumatoid Arthritis-associated Intravascular Large B-cell Lymphoma. — Kitai J, Sada RM, Yamaguchi S, Shinde A, Maruyama W Internal medicine (Tokyo, Japan) (2025)
[91]
The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumatica. — Nettleton E, Carlson K, Putman M The Lancet. Rheumatology (2025)
[92]
Exploration of Risk Factors for Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Retrospective Study. — Feng M, Meng F, Jia Y, Wang Y, Ji G, Gao C et al. Inflammation (2025)
[93]
Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology. — Cacciapaglia F, Spinelli FR, Erre GL, Piga M, Sakellariou G, Manfredi A et al. European journal of internal medicine (2025)
[94]
New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registry. — Spandorfer R, Kane K, Pappas DA, Kremer J, Reed G, Curtis JR et al. Seminars in arthritis and rheumatism (2025)
[95]
Tocilizumab does not ameliorate inflammation-induced left ventricular dysfunction in a collagen-induced arthritis rat model. — Manilall A, Mokotedi L, Gunter S, Roux RL, Fourie S, Millen AM Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology (2025)
[96]
Multimorbidity Patterns and Rheumatoid Arthritis Disease Outcomes: Findings From a Multicenter, Prospective Cohort. — Dutt S, Roul P, Yang Y, Johnson TM, Michaud K, Sauer B et al. Arthritis care & research (2025)
[97]
Endovascular solutions for symptomatic free-floating thrombus in thoracic aorta in rheumatoid arthritis patients: Two clinical cases. — Mastrangelo G, Di Sebastiano P, Palazzo V Vascular (2025)
[98]
Serum Levels of Trace Elements (Magnesium, Iron, Zinc, Selenium, and Strontium) are Differentially Associated with Surrogate Markers of Cardiovascular Disease Risk in Patients with Rheumatoid Arthritis. — Vera E, Vallvé JC, Linares V, Paredes S, Ibarretxe D, Bellés M Biological trace element research (2025)
[99]
Identifying the genetic association between rheumatoid arthritis and the risk of pulmonary arterial hypertension. — Yang L, Wang X, Gu B, Su D Clinical rheumatology (2025)
[100]
Effects of 17β estradiol on blood pressure elevation in ovariectomized rats with collagen-induced arthritis via modulation of oxidative stress, inflammation, fibrosis, and apoptosis in the aorta involving TLR4/NOX4/NF-kβ and TGFβ1/fibronectin/α-SMA pathways. — Govindasamy N, Barman M, Salleh N, Giribabu N, Shahzad H Naunyn-Schmiedeberg's archives of pharmacology (2025)

Share:Twitter Reddit LinkedIn